Michael E. Faerm
Director of Finance/CFO at VIRACTA THERAPEUTICS, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ivor Royston | M | 79 | 17 years | |
| Melody Burcar | F | 41 | 2 years | |
| Odysseas Kostas | M | 49 | 7 years | |
| Mark Rothera | M | 61 | 2 years | |
| Roger Pomerantz | M | 67 | 4 years | |
| Flavia Borellini | M | 64 | 3 years | |
| Laura Bessen | M | 61 |
Artiva Biotherapeutics, Inc.
 Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | 2 years |
| Jane Chung | F | 53 | 2 years | |
| Sam Murphy | M | 47 | 5 years | |
| Stephen Rubino | M | 65 | 3 years | |
| Jane Barlow | M | 63 | 3 years | |
| Elizabeth Hougen | F | 62 |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | 3 years |
| Christopher Fenimore | M | 53 | 21 years | |
| Linda Kozick | F | 66 |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | 3 years |
| Ashleigh Barreto | F | - | 3 years | |
| Barry Simon | M | 59 | 3 years | |
| Arthur Ryan | M | 81 | 21 years | |
| Thomas Darcy | M | 74 | 3 years | |
| Thorsten Graef | M | - |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | 2 years |
| Stewart M. Brown | M | - | 2 years | |
| Cheryl A. Madsen | F | - | - | |
| James Bucher | M | 59 | 1 years | |
| Edith Perez | M | 67 |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | 2 years |
| Ayman El-Guindy | M | - | 3 years | |
| Patric Nelson | M | - | 3 years | |
| Biljana Nadjsombati | F | - | 3 years | |
| Darrel Cohen | M | 59 | 1 years | |
| Donald Strickland | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael W. Aguiar | M | 57 | 13 years | |
| Thomas J. Farrell | M | 60 |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | 2 years |
| Julia Eastland | F | 59 | 6 years | |
| George Bickerstaff | M | 68 | 6 years | |
| Pat LePore | M | 69 | 2 years | |
| Lisa Lee | F | - |
Merrill Lynch & Co., Inc.
| 9 years |
| Terrence Kearney | M | 69 | 2 years | |
| Louis Yu | M | 73 | 6 years | |
| Donna Mitchell St. Amant | F | - |
Merrill Lynch & Co., Inc.
| 6 years |
| Wendy Lai | F | - |
Merrill Lynch & Co., Inc.
| 7 years |
| Kim Bernall | F | - |
Merrill Lynch & Co., Inc.
| 4 years |
| Eric Scott Dobbin | M | 62 |
Merrill Lynch & Co., Inc.
| 6 years |
| Jon Savas | M | - |
Merrill Lynch & Co., Inc.
| 5 years |
| Omar Jaffrey | M | - |
Merrill Lynch & Co., Inc.
| 5 years |
| James L. Cunningham | M | 51 |
Merrill Lynch & Co., Inc.
| 2 years |
| Brian Doe | M | - |
Merrill Lynch & Co., Inc.
| 9 years |
| Daniel A. Rubenstein | M | - |
Merrill Lynch & Co., Inc.
| 6 years |
| Young M. Kwon | M | - |
Merrill Lynch & Co., Inc.
| 5 years |
| Dan Volk | M | - |
Merrill Lynch & Co., Inc.
| - |
| Ush Patel | M | - |
Merrill Lynch & Co., Inc.
| 7 years |
| Scott Higginbotham | M | - |
Merrill Lynch & Co., Inc.
| - |
| Marcelo Salomon | M | - |
Merrill Lynch & Co., Inc.
| 4 years |
| Robert Colligan | M | 52 |
Merrill Lynch & Co., Inc.
| 3 years |
| Jonathan Santelli | M | 53 |
Merrill Lynch & Co., Inc.
| 8 years |
| Mike Stephenson | M | - |
Merrill Lynch & Co., Inc.
| 6 years |
| Fabián Alejandro de Paul | M | 60 |
Merrill Lynch & Co., Inc.
| 2 years |
| Gary Cohen | M | - |
Merrill Lynch & Co., Inc.
| 2 years |
| Foruhar Madjlessi | M | 56 |
Merrill Lynch & Co., Inc.
| 8 years |
| Kevin Michael Cuff | M | - |
Merrill Lynch & Co., Inc.
| 11 years |
| Anthony Gibney | M | 53 |
Merrill Lynch & Co., Inc.
| 10 years |
| Frank Kelly | M | - |
Merrill Lynch & Co., Inc.
| 2 years |
| Terrence James Loughran | M | - |
Merrill Lynch & Co., Inc.
| 4 years |
| Mark Hickson | M | 57 |
Merrill Lynch & Co., Inc.
| 15 years |
| Anthony Lin | M | - |
Merrill Lynch & Co., Inc.
| 4 years |
| Joseph Michael Barry | M | - |
Merrill Lynch & Co., Inc.
| 25 years |
| Gregory Z. Rush | M | - |
Merrill Lynch & Co., Inc.
| - |
| Doran Joseph Adhami | M | - |
Merrill Lynch & Co., Inc.
| 5 years |
| Michael Carlton Murray | M | - |
Merrill Lynch & Co., Inc.
| 16 years |
| Mike Gray | M | - |
Merrill Lynch & Co., Inc.
| - |
| Mark Kastan | M | - |
Merrill Lynch & Co., Inc.
| 4 years |
| Chris Carroll | M | - |
Merrill Lynch & Co., Inc.
| 3 years |
| Mina Koide | F | - |
Merrill Lynch & Co., Inc.
| 3 years |
| Bradley Howard Meyers | M | - |
Merrill Lynch & Co., Inc.
| 2 years |
| Bruce J. Schanzer | M | 55 |
Merrill Lynch & Co., Inc.
| 6 years |
| Tim Bepler | M | - |
Merrill Lynch & Co., Inc.
| 2 years |
| Mark L. Constant | M | - |
Merrill Lynch & Co., Inc.
| 8 years |
| Megan W. Kulick | F | - |
Merrill Lynch & Co., Inc.
| 7 years |
| Scott Graves | M | 53 |
Merrill Lynch & Co., Inc.
| 1 years |
| David K. Juncker | M | - |
Merrill Lynch & Co., Inc.
| 2 years |
| Paul J. Matus | M | - |
Merrill Lynch & Co., Inc.
| - |
| David Pickering | M | - |
Merrill Lynch & Co., Inc.
| 6 years |
| Marc Pandraud | M | 66 |
Merrill Lynch & Co., Inc.
| - |
| Kevin L. Bespolka | M | 61 |
Merrill Lynch & Co., Inc.
| 8 years |
| Steve Maniago | M | - |
Merrill Lynch & Co., Inc.
| 2 years |
| Michael Peterson | M | 63 |
Merrill Lynch & Co., Inc.
| 4 years |
| Grace Bianchi | F | - |
Merrill Lynch & Co., Inc.
| 4 years |
| David S. Ram | M | - |
Merrill Lynch & Co., Inc.
| - |
| Michael Goller | M | 49 |
Merrill Lynch & Co., Inc.
| 2 years |
| Michael Cavanaugh | M | 50 |
Merrill Lynch & Co., Inc.
| 3 years |
| John Hele | M | 65 |
Merrill Lynch & Co., Inc.
| 10 years |
| Maureen Murphy | F | - |
Merrill Lynch & Co., Inc.
| 1 years |
| Julie Levenson | F | 61 |
Merrill Lynch & Co., Inc.
| 3 years |
| Jerry Mandel | M | 60 |
Merrill Lynch & Co., Inc.
| 5 years |
| Chris Shonk | M | - |
Merrill Lynch & Co., Inc.
| 3 years |
| Sumit Roy | M | 54 |
Merrill Lynch & Co., Inc.
| 2 years |
| Iain Franks | M | - |
Merrill Lynch & Co., Inc.
| 2 years |
| Rick Scott | M | - |
Merrill Lynch & Co., Inc.
| 8 years |
| Jennifer O'Hara Martin | F | - |
Merrill Lynch & Co., Inc.
| 3 years |
| Robert E. Wahlman | M | 68 |
Merrill Lynch & Co., Inc.
| 8 years |
| Christopher Brown | M | - |
Merrill Lynch & Co., Inc.
| 6 years |
| Adam Williams | M | - |
Merrill Lynch & Co., Inc.
| 8 years |
| Smith Brian | M | - |
Merrill Lynch & Co., Inc.
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael E. Faerm
- Personal Network
